Summary of Sarepta Therapeutics Q4 2025 Earnings Call

1Key Financial Results and Metrics

Total Revenues: $2.2 billion for the full year 2025, a 16% increase year-over-year.

Net Product Revenue: $1.86 billion, with $966 million from PMO therapies and $899 million from ELEVIDYS.

Q4 Net Product Revenue: $259 million from PMOs and $110 million from ELEVIDYS.

Cash Position: Ended 2025 with $954 million in cash and investments, growing by $89 million in Q4.

Operating Loss: GAAP operating loss of $700 million; non-GAAP operating loss of $492 million.

Guidance for 2026: Total net product revenue expected between $1.2 billion and $1.4 billion, with Q1 anticipated to be flat or down 15% from Q4 2025.

2Strategic Updates and Business Highlights

Therapeutic Portfolio: Four approved therapies, including three PMOs and ELEVIDYS, which has received traditional approval for ambulatory patients.

Pipeline Development: Advancements in siRNA programs for various neuromuscular and CNS diseases, with ongoing trials for DM1, FSHD, and Huntington's disease.

ELEVIDYS Initiatives: Plans to address information deficits regarding ELEVIDYS to improve physician and patient understanding of its benefits, especially after safety concerns in 2025.

Commercial Strategy: Expansion of the sales force and educational initiatives aimed at increasing awareness and understanding of ELEVIDYS.

3Forward Guidance and Outlook

Revenue Projections: Expected total net product revenue of $1.2 billion to $1.4 billion for 2026, with the lower end reflecting current educational efforts' impact.

Q1 2026 Revenue: Anticipated to be flat to down 15% compared to Q4 2025.

Long-term Confidence: Strong belief in the demand for ELEVIDYS and its transformative potential, with expectations for increased sales as educational initiatives take effect.

4Bad News, Challenges, or Points of Concern

ELEVIDYS Performance: Q4 revenues were impacted by a severe flu season and rescheduled infusions, leading to uncertainty in near-term sales.

Market Dynamics: Concerns about the cannibalization of PMOs by ELEVIDYS, though some physicians are still using both therapies concurrently.

Safety Events: Tragic events in 2025 created uncertainty around ELEVIDYS, affecting physician and patient confidence.

Competitive Pressures: Potential competition from emerging exon-skipping therapies, particularly Dyne's EXONDYS, which could impact PMO sales.

5Notable Q&A Insights

CEO Transition: Doug Ingram announced plans to retire by the end of 2026, citing family commitments, which raised questions about leadership continuity.

ELEVIDYS Education: Metrics for success in educational initiatives will focus on enrollment forms and infusion rates, with expectations for improvement in the second half of 2026.

DM1 and FSHD Trials: Anticipation of preliminary data from ongoing trials, with a focus on safety and muscle concentration as key indicators of success.

Newborn Screening Impact: The addition of DMD to the federal screening panel is expected to create long-term opportunities, though its immediate impact on revenue is limited. This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges faced, and insights from the Q&A session, providing a comprehensive overview of Sarepta's current position and outlook.